Calliditas Therapeutics AB (NAS:CALT)
$ 21.5001 -0.4999 (-2.27%) Market Cap: 577.06 Mil Enterprise Value: 576.39 Mil PE Ratio: 0 PB Ratio: 18.85 GF Score: 49/100

Q2 2020 Calliditas Therapeutics AB Earnings Call Transcript

Aug 13, 2020 / 12:30PM GMT
Release Date Price: $22.03 (-4.47%)
Operator

Ladies and gentlemen, welcome to Calliditas Therapeutics Q2 2020. (Operator Instructions)

Today, I am pleased to present CEO, Renee Aguiar-Lucander; CFO, Fredrik Johansson; and CSO, Johan Haggblad. Please go ahead with your meeting.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you very much, and welcome to this Q2 call. I'm going to start on Page 3 and just take you through the summary of key events for this quarter, Q2.

So in June, we completed an IPO on NASDAQ Global Select Market in the U.S. The gross proceeds of the offering was $90 million. And we actually were the first ever kind of Swedish life science company to actually raise capital in an IPO on the NASDAQ Select, which we think is pretty exciting. And the process itself was there was a brief kind of like a 4-day roadshow, which now all of you who have seen what's happened in the kind of capital market due to COVID-19 has become quite the standard. The offer was multiple times that were subscribed, and we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot